• Jinyong Kim, Ja Min Byun, Junshik Hong, Youngil Koh, Dong-Yeop Shin, Tae Min Kim, Sung-Soo Yoon, Hyunkyung Park, and Inho Kim.
• Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
• Medicine (Baltimore). 2024 Feb 16; 103 (7): e37100e37100.

AbstractLymphoblastic lymphoma (LBL) is a rare, aggressive non-Hodgkin lymphoma (NHL) that has no established therapeutic approaches. The aim of this study was to investigate optimal treatments and prognostic risk models for patients with LBL in East Asia. We retrospectively examined the clinical data and treatment courses of adult patients diagnosed as LBL by WHO 2017 classification system. Median overall survival (OS) of the 78 patients with LBL was 38.3 months. There was no significant difference in OS between the patients who were treated with acute lymphoblastic leukemia (ALL)-like protocols and with NHL-like protocols (72.4 months vs 37.5 months, respectively, P = .546). The patients treated with ALL-like protocols had significantly shorter progression-free survival (PFS) (median 11.7 months for ALL-like protocols vs 27.0 months for NHL-like protocols, P = .030). A multivariable analysis found that central nervous system (CNS) prophylaxis, relapse of CNS lesions, leukemic transformation, and response to initial treatment were risk factors for OS of patients with LBL. Hematopoietic stem cell transplantation had no survival benefit, compared with chemotherapy-only treatment. Less intensive chemotherapy may be more optimal for patients in East Asia. Prophylaxis and management of CNS lesions should be emphasized throughout the treatment of LBL.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…